Phase 2 Research on Alzheimer's Psychosis Using Investigational Agent ACP-204 Begins at Acadia.

Published Date: 03 Dec 2023

Building on the insights from pimavanserin (Nuplazid) in the management of neuropsychiatric symptoms, ACP-204 is an inverse agonist at the 5-HT2A receptor.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

Study finds that AI is better at forecasting the risk of developing cancer.

3.

Kate Middleton and Remission: Oncologists Weigh In

4.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

5.

What Role Should Genomic Classifier Testing Play in Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot